Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With All Chips On Phase II Antibody Conjugate, CuraGen Eyes Strategic Options

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech’s cash coffers are well stocked, but out-license of GPNMB-targeting cancer drug – or outright sale of the company – could be next.

You may also be interested in...



2009 Is ImmunoGen’s Make-Or-Break Year

The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.

2009 Is ImmunoGen’s Make-Or-Break Year

The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.

Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma

SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel